News
NRSN
0.7230
+0.42%
0.0030
BUZZ-U.S. STOCKS ON THE MOVE-Regenxbio, Repay,  Natera, Fortune Brands
Reuters · 2d ago
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3
TipRanks · 2d ago
BUZZ-NeuroSense rises as nerve disease drug shows promise in study
Reuters · 2d ago
NeuroSense Says Phase 2b ALS Study Meets Primary Endpoint
NASDAQ · 2d ago
NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint
TipRanks · 2d ago
NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint
Benzinga · 2d ago
NeuroSense says Phase 2b ALS trial meets primary endpoint, cuts TDP-43 vs placebo (p=0.0421)
PUBT · 2d ago
NEUROSENSE THERAPEUTICS - PRIMEC SHOWS SIGNIFICANT TDP-43 REDUCTION AT DAY 180 AND DAY 540 IN PHASE 2B ALS STUDY
Reuters · 2d ago
Weekly Report: what happened at NRSN last week (0622-0626)?
Weekly Report · 2d ago
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
TipRanks · 6d ago
NeuroSense Therapeutics Announces Data From Its Phase 2 RoAD Trial Of PrimeC In Alzheimer's Disease Demonstrates Multiple Protein Biomarker Changes; Distinctive Changes Also Seen In Levels Of Other Major Neurodegenerative Disease Misfolding Proteins
Benzinga · 6d ago
NeuroSense reports positive Phase 2 RoAD biomarker findings for PrimeC in Alzheimer’s disease study
PUBT · 6d ago
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Viking Therapeutics (VKTX)
TipRanks · 6d ago
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
PR Newswire · 6d ago
NeuroSense joins EverythingALS community event on PrimeC data in ALS
PUBT · 06/22 13:03
Weekly Report: what happened at NRSN last week (0615-0619)?
Weekly Report · 06/22 09:55
Top Brass Double Down: Neurosense Leaders Make Bold Insider Move
TipRanks · 06/18 02:03
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/17 21:06
Weekly Report: what happened at NRSN last week (0608-0612)?
Weekly Report · 06/15 09:56
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC
TipRanks · 06/11 13:22
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease